Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2012-07-23 Board/Management Inform…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Director Appointment/Resignation 4 pages 120.8KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated July 24, 2012, regarding the appointment of Mr. Greg Brown as a non-executive director of Genetic Technologies Limited. It includes biographical details about Mr. Brown, statements from the Chairman, and an Appendix 3X Initial Director’s Interest Notice, which is a regulatory form related to director appointments and their interests in securities. There are no financial statements, earnings data, or detailed management discussion of financial results. The document is primarily an announcement of a board/management change and includes a regulatory filing (Appendix 3X) related to director interests. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (8018 characters) and content confirm it is not a brief report publication announcement or a certification. Hence, the classification is MANG with high confidence.
2012-07-23 English
Non-coding licensing update 2 pages 118.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated July 9, 2012, providing an update on Genetic Technologies Limited's non-coding DNA technology licensing program. It discusses the expansion of a legal assertion arrangement with Sheridan Ross P.C., details about a US Patent and Trademark Office re-examination of a specific patent, and related litigation matters. The content focuses on legal and licensing updates rather than financial results, management changes, or shareholder voting. It is not a full financial report, earnings release, or regulatory certification. The document is a market update announcement about intellectual property and legal proceedings related to patents. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-07-08 English
Appendix 3B 7 pages 64.5KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to securities issuance and quotation. It details the issuance of unlisted options under an Employee Share Option Plan, including number of securities, terms, and quotation application. The content is regulatory in nature, focused on announcing a new securities issue and applying for quotation on the ASX. It does not contain financial statements, management discussion, or earnings data. The document length is about 10,598 characters, which is consistent with a detailed announcement rather than a full financial report. Therefore, this document fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2012-05-29 English
BREVAGen credentialing update 3 pages 119.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated May 22, 2012, providing an update on sales and reimbursement progress for the BREVAGen™ test by Genetic Technologies Limited. It discusses sales figures, credentialing contracts with PPOs, state certification updates, and general company information. There are no financial statements, detailed financial performance data, or comprehensive management analysis typical of annual or interim reports. The document is a corporate update on commercial progress and operational milestones rather than a financial report or regulatory filing. It is not a call transcript, audit report, or governance document. The content fits best as a Capital/Financing Update (CAP) because it relates to sales, revenue collection, and reimbursement progress, which are aspects of the company's capital and financing activities. The document length (9295 characters) and detailed operational update support this classification with high confidence.
2012-05-21 English
Settlement with GeneSeek 2 pages 115.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated May 9, 2012, reporting the execution of a Settlement and License Agreement between Genetic Technologies Limited and GeneSeek Inc. It discusses the terms of the agreement, ongoing discussions, and provides company background and contact information. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a disclosure of a business agreement and settlement, not a financial report or earnings release. It is not a regulatory filing about voting, management changes, or capital structure. The content fits best as a general regulatory announcement about a material business event, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2012-05-08 English
Appendix 4C - quarterly 9 pages 94.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 March 2012'. It contains detailed operational updates, cash flow statements, financing activities, and corporate matters for the quarter. The presence of Appendix 4C, which is a standard quarterly cash flow report required by the ASX, confirms this is a quarterly report. The document includes substantive financial data and analysis for the quarter, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2012
2012-04-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.